Literature DB >> 11252817

Proliferative and cytotoxic capabilities of CD16+CD56- and CD16+/-CD56+ natural killer cells.

S R Søndergaard1, H Ullum, B K Pedersen.   

Abstract

Natural killer (NK) cells can be divided into several subpopulations according to their expression of the surface antigens CD16 and CD56. The modest quantity of NK cells in the blood available for functional analysis has been a limitation in studies of NK cell subpopulations. In the present study, epinephrine infusion was used to induce lymphocytosis before immunomagnetic methods were applied to isolate CD16+/-CD56+ and CD16+CD56- CD3- NK cells. These subpopulations were compared according to their proliferative and cytotoxic capabilities in 10 human immunodeficiency virus (HIV)-infected individuals and 5 healthy controls. The CD16+CD56- NK cell subgroup had a higher proliferative capacity, whereas the CD16+/-CD56+ NK cell subgroup was mainly cytotoxic, and unaffected by HIV serostatus. This study thus suggests that NK cell phenotypes more strongly predict NK cell function than HIV serostatus. This assertion should be considered when studying NK cell function in subjects with a deviating composition of NK cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11252817     DOI: 10.1111/j.1600-0463.2000.tb00006.x

Source DB:  PubMed          Journal:  APMIS        ISSN: 0903-4641            Impact factor:   3.205


  8 in total

1.  Are increased frequency of macrophage-like and natural killer (NK) cells, together with high levels of NKT and CD4+CD25high T cells balancing activated CD8+ T cells, the key to control Chagas' disease morbidity?

Authors:  D M Vitelli-Avelar; R Sathler-Avelar; R L Massara; J D Borges; P S Lage; M Lana; A Teixeira-Carvalho; J C P Dias; S M Elói-Santos; O A Martins-Filho
Journal:  Clin Exp Immunol       Date:  2006-07       Impact factor: 4.330

2.  Differential expression of perforin in cytotoxic lymphocyte in HIV/AIDS patients of China.

Authors:  Wang Qi; Jiang Yongjun; Wang Yanan; Zhang Zining; Han Xiaoxu; Liu Jing; Shang Hong
Journal:  J Clin Immunol       Date:  2006-06-13       Impact factor: 8.317

Review 3.  Dendritic cells and natural killer cells in the pathogenesis of HIV infection.

Authors:  Claudio Fortis; Guido Poli
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

4.  Characterization of CD56-/CD16+ natural killer (NK) cells: a highly dysfunctional NK subset expanded in HIV-infected viremic individuals.

Authors:  Domenico Mavilio; Gabriella Lombardo; Janet Benjamin; Diana Kim; Dean Follman; Emanuela Marcenaro; M Angeline O'Shea; Audrey Kinter; Colin Kovacs; Alessandro Moretta; Anthony S Fauci
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-07       Impact factor: 11.205

5.  CD56negCD16⁺ NK cells are activated mature NK cells with impaired effector function during HIV-1 infection.

Authors:  Jeffrey M Milush; Sandra López-Vergès; Vanessa A York; Steven G Deeks; Jeffrey N Martin; Frederick M Hecht; Lewis L Lanier; Douglas F Nixon
Journal:  Retrovirology       Date:  2013-12-18       Impact factor: 4.602

6.  Lymphocyte subpopulations in myocardial infarction: a comparison between peripheral and intracoronary blood.

Authors:  Natalia Lluberas; Natalia Trías; Andreína Brugnini; Rafael Mila; Gustavo Vignolo; Pedro Trujillo; Ariel Durán; Sofía Grille; Ricardo Lluberas; Daniela Lens
Journal:  Springerplus       Date:  2015-12-01

7.  Role of Circulating T Follicular Helper Cells and Stem-Like Memory CD4+ T Cells in the Pathogenesis of HIV-2 Infection and Disease Progression.

Authors:  Sivasankaran Munusamy Ponnan; K K Vidyavijayan; Kannan Thiruvengadam; Nancy Hilda J; Manikannan Mathayan; Kailapuri Gangatharan Murugavel; Luke Elizabeth Hanna
Journal:  Front Immunol       Date:  2021-04-16       Impact factor: 7.561

Review 8.  Regulation of MHC I Molecules in Glioblastoma Cells and the Sensitizing of NK Cells.

Authors:  Timo Burster; Fabian Gärtner; Christiane Bulach; Anuar Zhanapiya; Adrian Gihring; Uwe Knippschild
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.